---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-097534"
form_type: "8-K"
ticker: "ENGN"
cik: "0001980845"
company_name: "enGene Therapeutics Inc."
filed_at: "2026-03-09T23:59:59+00:00"
generated_at: "2026-05-15T18:14:15.086967+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# enGene Q1 net loss $29.8M; cash $312.5M; LEGEND data update at spring 2026 conference

## Summary
- Net loss $29.8M ($0.44/share) vs $24.6M ($0.48/share) year ago; operating expenses $31.2M.
- Cash & marketable securities $312.5M; expected runway into 2H 2028.
- Expanded Hercules Capital debt facility to $125M for detalimogene development & commercial prep.
- LEGEND pivotal cohort 63% CR at any time (n=62); BLA filing planned for 2H 2026.
- 12-month CR data expected 2H 2026; CDRP program selected by FDA.

## SEC filing metadata
- accession: 0001193125-26-097534
- form_type: 8-K
- ticker: ENGN
- cik: 0001980845
- company_name: enGene Therapeutics Inc.
- filed_at: 2026-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1980845/000119312526097534/0001193125-26-097534-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1980845/000119312526097534/engn-20260309.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-097534
- JSON: https://secwatch.observer/filing/0001193125-26-097534.json
- Plain text: https://secwatch.observer/filing/0001193125-26-097534.txt

## Key facts
- Earnings Releases
  enGene Therapeutics Inc. reported first quarter ended January 31, 2026 results: net income net loss attributable to common shareholders was approximately $29.8 million, EPS $0.44 per share.
  - Period: first quarter ended January 31, 2026
  - Net income: net loss attributable to common shareholders was approximately $29.8 million
  - EPS: $0.44 per share
  - Result: reported results
  source text: enGene Reports First Quarter 2026 Financial Results and Provides Business Update
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000119312526097534/0001193125-26-097534-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.